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VisionSchizophrenia is characterized by anomalous perceptual experiences (e.g., sensory irritation, inundation, and
ﬂooding) and speciﬁc alterations in visual perception.We aimed to investigate the effects of short-term antipsy-
chotic medication on these perceptual alterations. We assessed 28 drug-naïve ﬁrst episode patients with schizo-
phrenia and 20 matched healthy controls at baseline and follow-up 8 weeks later. Contrast sensitivity was
measured with steady- and pulsed-pedestal tests. Participants also received a motion coherence task, the Struc-
tured Interview for Assessing Perceptual Anomalies (SIAPA), and the Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS). Proton magnetic resonance spectroscopy was used to measure gamma-
aminobutyric acid (GABA) levels in the occipital cortex (GABA/total creatine [Cr] ratio). Results revealed that,
comparing baseline and follow-up values, patients with schizophrenia exhibited a marked sensitivity reduction
on the steady-pedestal test at low spatial frequency. Anomalous perceptual experiences were also signiﬁcantly
ameliorated. Antipsychotic medications had no effect on motion perception. RBANS scores showed mild
improvements. At baseline, but not at follow-up, patients with schizophrenia outperformed controls on the
steady-pedestal test at low spatial frequency. The dysfunction of motion perception (higher coherence threshold
in patients relative to controls) was similar at both assessments. There were reduced GABA levels in schizophre-
nia at both assessments, whichwere not related to perceptual functions. These results suggest that antipsychotics
dominantly affect visual contrast sensitivity and anomalous perceptual experiences. The prominent dampening
effect on low spatial frequency in the steady-pedestal test might indicate the normalization of putatively overac-
tive magnocellular retino-geniculo-cortical pathways.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Patients with schizophrenia often report anomalous perceptual
experiences that are subjectively and phenomenologically different
from hallucinations and other positive psychotic symptoms. These ex-
periences include disturbingly high intensity of environmental stimuli,
feelings of being ﬂooded and inundated, and inability to focus attention
to relevant details (Bunney et al., 1999; Klosterkötter et al., 2001;
Phillipson and Harris, 1985), which is most prevalent and severe inles/degree; Cr, creatine; GABA,
fference; M, magnocellular; P,
ale; RBANS, Repeatable Battery
PA, Structured Interview for
lty of Medicine, Department of
s.gyula@med.u-szeged.hu
ghts reserved.the auditory and visual sensory modalities (Bunney et al., 1999;
Martín-Reyes et al., 2010; Mendoza Quiñones et al., 2007).
In a series of studies, we explored the possible psychophysical corre-
lates of anomalous perceptual experiences, with a special reference to
the visual modality (Kéri et al., 2005; Kiss et al., 2010). Initially, we
used the framework of the retino-geniculo-cortical magnocellular (M)
and parvocellular (P) visual pathways, which originate in the retina
and are theoretically responsible for the processing of different kinds
of stimulus features (M pathways: low spatial frequencies [rough reso-
lution of objects], luminance contrast, motion; P pathways: high spatial
frequencies [ﬁne resolution of objects], color contrast, form) (Nassi and
Callaway, 2009). However, despite the fact that this perceptual hypoth-
esis received an extensive attention in the literature of schizophrenia
(e.g., reviewed by Butler et al., 2008; Javitt, 2009), the exact psychophys-
ical distinction ofMandP pathways has been debated (Goodbourn et al.,
2012; Merigan and Maunsell, 1993; Skottun and Skoyles, 2007).
During past decades of research, Pokorny and colleagues developed
a new method for the separation of putative M and P pathways, which
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pulsed-pedestal paradigm, the target detection period, during which
participants are requested to detect a brieﬂy ﬂashed low-contrast grat-
ing, is preceded by an adaptation period containing a homogeneous
high luminance ﬁeld. During the target detection period, the luminance
of the background ﬁeld is abruptly reduced, which saturates M path-
ways, but not P pathways. Therefore, the pulsed-pedestal paradigm
shifts information processing toward the P pathways. In the steady-
pedestal condition, M pathways are not saturated and therefore brieﬂy
presented stimuli with low contrast and low spatial frequency are
thought to be dominantly processed by these pathways (Fig. 1; for a
critical review and comparison with other methods, see Skottun and
Skoyles, 2011).
Using the steady-/pulsed-pedestal tasks in drug-naïve ﬁrst-episode
schizophrenia patients, Kiss et al. (2010) found abnormally heightened
sensitivity for putatively M-biased stimuli, indicating an overactive vi-
sual response. A similar ﬁnding was reported by Antal et al. (1998)
and Chen et al. (2003) using conventional contrast sensitivity measure-
ments. Critically, higher M-biased contrast sensitivity values were asso-
ciated with increased scores on a standardized scale for anomalous
perceptual experiences (Kiss et al., 2010).
The primary purpose of the present study was to investigate the ef-
fect of short-termantipsychoticmedication on visual contrast sensitivity
and anomalous perceptual experiences in ﬁrst-episode schizophrenia.
Given that, by the inhibition of dopamine D2 receptors in the retina, an-
tipsychotics have a profound effect on contrast processing (Bulens et al.,
1989; Harris et al., 1990; Kéri et al., 2002), we hypothesized rapidly
dampened contrast sensitivity and, if it is indeed related to anomalous
perceptual experiences, a parallel amelioration of subjective sensory
symptoms. Second, we assessed higher levels of visual processing, that
is, the perception of coherent motion. Extensive evidence suggests
thatmotion perception is impaired in schizophrenia and that it is related
to higher levels of cortical information processing (area MT/V5)
(Chen, 2011). However, the effect of antipsychotic medications on mo-
tion processing has not been clariﬁed. Third, we administered a battery
of neuropsychological tests to tackle changes in neurocognition (atten-
tion, memory, visual-spatial processing, and language) during therapy.
Past studies revealed a mild beneﬁcial effect of antipsychotics on
neurocognition (for meta-analyses, see Woodward et al., 2005, 2007).
Finally, we measured gamma-aminobutyric acid (GABA) concentration
in the occipital cortex before and after antipsychotic therapy and
compared that with perceptual changes. This ﬁnal aim of the studyFig. 1. Contrast sensitivity measurements. In the pulsed-pedestal test, the luminance of the b
information processing toward the parvocellular (P) pathways. In the steady-pedestal paradigwas based on the ﬁndings of Yoon et al. (2010) who identiﬁed a strong
positive correlation between occipital GABA concentration and visual
inhibition (orientation-speciﬁc surround suppression). These authors
hypothesized that decreased GABA concentration in the visual cortex
of patients with schizophrenia caused weakened visual inhibition
(Yoon et al., 2010).
2. Material and methods
2.1. Participants
Twenty-eight patients with ﬁrst-episode schizophrenia and twenty
healthy control volunteers participated in the study. Some of the partic-
ipants have been included in previous studies where details of recruit-
ment have been described (Kéri et al., 2010; Kiss et al., 2010; Szamosi
et al., 2012). There were two recruitment centers in Southern Hungary
and Budapest. Patients were referred from the whole country. None of
the patients received previous treatment with psychotropic medica-
tions, and theywere therefore drug-naïve at the time of baseline assess-
ment. The mean duration of untreated psychosis was 9.7 months
(SD = 6.1). All participants received the Structured Clinical Interview
for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) (First et al.,
1996). We used the Positive and Negative Syndrome Scale (PANSS)
for the evaluation of clinical symptoms (Kay et al., 1987). Exclusion
criteria included neurological disorders, head injury, and history of psy-
choactive substance misuse. All participants had normal or corrected-
to-normal visual acuity. The clinical and demographic characteristics
are depicted in Table 1. The study was carried out in accordance with
the Declaration of Helsinki and was approved by the local ethics
board. After a full description of the study, participants gave written
informed consent.
2.2. Medications
We ﬁrst assessed the patients in a drug-naïve state (baseline). This
baseline assessment was followed by 8 weeks of treatment. The dose
and type of antipsychotic medications administered to patients were
at the discretion of the treating physician who was blind to the aims
of the study. All clinical scales and tests were administered by trained
and supervised clinical psychologists and psychiatrist who were blind
to the medication status of the patients. Patients received the following
medications: haloperidol (n = 1, 4 mg/day); olanzapine (n = 10,ackground ﬁeld is abruptly reduced to saturate magnocellular (M) pathways and to bias
m, the luminance of the background ﬁeld is constant.
Table 1
Clinical and demographic characteristics of the participants.
Schizophrenia
(n = 28)
Control
(n = 20)
Gender (male/female) 18/10 14/6
Age (years) 24.9 (8.3) 24.2 (6.9)
Education (years) 11.0 (3.9) 11.3 (3.6)
Positive and Negative
Syndrome Scale (PANSS)a
Positive
Baseline 18.4 (7.6) –
Follow-up 11.2 (3.4) –
Negative
Baseline 13.4 (6.9) –
Follow-up 9.9 (6.2) –
General
Baseline 56.4 (16.4) –
Follow-up 45.8 (12.3) –
Structured Interview for
Assessing Perceptual Anomalies (SIAPA)—
Visual Domain
Baseline 2.16 (1.5)
Follow-up 0.38 (0.8)
Data are mean (standard deviation). Statistical details are presented in the main text.
a Signiﬁcant reduction in scores (follow-up relative to baseline).
Fig. 2. Motion coherence. A percentage of dots are moving downward as illustrated by
white arrows. The remainder of dots moves in random directions.
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done (n = 11, dose: 2–6 mg/day); zuclopenthixol (n = 2; 25 mg/day).
Mood stabilizers (valproate, n = 5), benzodiazepines (alprazolam or
clonazepam, n = 16), and anticholinergics (biperiden, n = 5) were
allowed during the treatment period.
2.3. Anomalous perceptual experiences
We used the Structured Interview for Assessing Perceptual Anoma-
lies (SIAPA) for the assessment of subjective anomalous perceptual
experiences (Bunney et al., 1999). The SIAPA separately evaluates sen-
sory intensity, inundation or ﬂooding, and selective attention to exter-
nal stimuli in the ﬁve sensory modalities using a 0 (never occurred)–5
(always present) scale. For example, in the visual modality, participants
ratewhether lights seemmuchbrighter, the intensity of colors is greater
(i.e., more vivid), complex visual environments are bothersome, and he
or she is overwhelmed by multiple visual stimuli and cannot attend to
one of many simultaneous visual inputs (Bunney et al., 1999). In the
present study, we focused on the visual modality. Two independent
raters assessed each patient (kappa N 0.7).
2.4. Visual contrast sensitivity
The method of contrast sensitivity measurements was described
in details in previous publications (Alexander et al., 2005; Kiss
et al., 2010; Leonova et al., 2003; Pokorny and Smith, 1997). We
used a gamma-corrected ViewSonic PF815 monitor controlled by
an IBM-compatible PC. Stimuli were Gabor patches (size: 2.5° × 2.5°)
with a luminance-contrast proﬁle formed by the multiplication of a si-
nusoidal waveform with a Gaussian envelope (Fig. 1). Participants
were asked to detect of a brieﬂy ﬂashed low-contrast Gabor patch
(exposure time: 45 ms). The patch was presented in the center of a
square luminance pedestal (7.6° on a side, mean luminance: 12 cd/m2).
The pedestal was localized in the center of a homogeneous adapting
ﬁeld (12.0° on a side, mean luminance: 25 cd/m2), producing a lumi-
nance decrement (Fig. 1).
In the steady-pedestal paradigm, the pedestalwas presented contin-
uously, whereas in the pulsed-pedestal paradigm, the pedestal was
exposed only during the test period, together with the target Gabor
patch. In both paradigms, we used a 30-s adaptation period before the
test period.An experimental trialwas initiated by theparticipantwhenheor she
pressed the space bar on the computer keyboard, which was followed
by awarning tone immediately preceding the presentation of the target
patch. We asked the participants to judge whether the patch was hori-
zontal or vertical (key “1” for vertical and key “0” for horizontal). The
participants gave oral responses, which were entered by the experi-
menter. The order of steady- and pulsed-pedestal conditions was
randomized. In each condition, contrast thresholds were measured at
2 spatial frequencies (0.25 and 4 cycles/degree [c/d]) using an adaptive
staircasemethod.We used only 2 spatial frequencies in order to shorten
the duration of the testing session.
The staircase steps were calculated as follows (Treutwein, 1995):
Xnþ1 ¼ Xn−c= 2þmshift
 
Zn−ϕð Þ
Xn step size on trial n
c initial contrast value (40%)
mshift cumulative number of reversals
Zn observer's response (0 or 1)
ϕ targeted percent correct value (80%)
The staircase was terminated after the 12th reversal. The contrast
threshold was the average of the ﬁnal 6 reversals. Contrast sensitivity
was the inverse of the contrast threshold.2.5. Motion perception
We used Glass pattern stimuli to determine motion coherence
threshold (Glass, 1969; Kéri and Benedek, 2012; McKendrick et al.,
2006) (Fig. 2). During the measurement, a fraction of randomly chosen
dots moved in the same signal direction, whereas the remaining dots
did not move coherently (9 min arc/frame, 3 deg/s). We measured
coherence thresholds (percentage of coherently moving dots necessary
for stimulus detection) using a staircase procedure.
Table 2
Results from the ANOVA conducted on the contrast sensitivity data.
F p η2
Main effects
Group (1) 0.03 0.85 0.0
Time (2) 62.08 b0.0001 0.57
Stimulus (3) 96.65 b0.0001 0.68
Spatial frequency (4) 39.63 b0.0001 0.46
Interactions
1 × 2 52.65 b0.0001 0.53
1 × 3 8.44 0.01 0.16
1 × 4 0.18 0.68 0.0
2 × 3 26.19 b0.0001 0.36
2 × 4 9.22 0.004 0.17
3 × 4 168.15 b0.0001 0.79
1 × 2 × 3 28.79 b0.0001 0.38
1 × 2 × 4 19.50 b0.001 0.29
1 × 3 × 4 1.47 0.23 0.03
2 × 3 × 4 13.42 0.0006 0.23
1 × 2 × 3 × 4 10.1 0.003 0.18
df = 1,46; group: schizophrenia vs. control; time: baseline vs. follow-up; stimulus:
steady- vs. pulsed-pedestal; spatial frequency: 0.25 c/d vs. 4 c/d.
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Volunteers completed the RBANS battery, which includes 12 neuro-
psychological tests classiﬁed according to 5 index scores (Gold et al.,
1999; Juhász et al., 2003; Randolph et al., 1998). Each index score is
standardized (mean: 100, SD = 15 based on a normative study group
of 200 healthy Hungarian volunteers, 20–80 years of age). The 5
RBANS index domains are as follows: (1) immediate memory (word
list learning [10words repeated in four trials], story recall in two trials);
(2) language (confrontation naming of 10 pictures, category ﬂuency);
(3) visuospatial functions (ﬁgure copy, line orientation); (4) attention
(digit span, digit-symbol coding); (5) delayed memory (delayed recall
of the story, complex ﬁgure, and word list, recognition of the word
list). The RBANS battery has two psychometrically matched forms, “A”
and “B”, providing an opportunity to avoid practice effects by repeating
the same tests twice. We report the overall RBANS score (average of the
5 domain scores) to increase statistical power.
2.7. Spectroscopic measurements
We measured GABA with proton magnetic resonance spectroscopy
(MRS) using a Siemens Trio 3 T scanner. We used the scanning param-
eters and MRS protocol of Yoon et al. (2010). The scanning parameters
were as follows: repetition time, 1500 ms; echo time, 68 ms; edit fre-
quency 1.9 ppm; delta frequency, −1.7; edit pulse bandwidth, 45 Hz;
number of excitations, 256; and scan duration, 6.5 min. We placed
paired surface coils under the occiput. The region-of-interest was a
35 × 30 × 25 mm voxel centered on the calcarine sulcus (posterior
border: 7 mm anterior the dura mater). The method of Mescher et al.
(1998) was the basis of the measurement of total GABA, as used by
Yoon et al. (2010). The ratio of total GABA/total creatine (Cr) signal
from the occipital cortex was the dependent measure.
2.8. Statistical analysis
We used STATISTICA 11 (StatSoft, Inc., Tulsa) software. All statistical
tests were designed before the experiment. After the quality analysis of
data (Kolmogorov–Smirnov and Levene's tests),measureswere entered
into analyses of variance (ANOVA). Tukey Honestly Signiﬁcant Differ-
ence (HSD) tests were used for post-hoc comparisons. Clinical scale
scores were comparedwith two-tailed t-tests. Cohen's effect size values
(d) were calculated to characterize differences in RBANS scores. We
used Pearson's product moment correlation coefﬁcients to determine
the relationship between psychophysical data and GABA levels. The
level of statistical signiﬁcance was set at α b 0.05.
3. Results
3.1. SIAPA and PANSS scores
Table 1 shows the SIAPAand PANSS scores at baseline and follow-up.
Patients with schizophrenia displayed signiﬁcant improvements in
PANSS scores (positive: t(54) = 4.49, p b 0.001; negative: t(54) = 2.0,
p = 0.05; general: t(54) = 2.75, p b 0.05). We also observed a signiﬁ-
cant reduction in SIAPA scores (t(54) = 5.83, p b 0.0001).
3.2. Contrast sensitivity
The ANOVA conducted on the contrast sensitivity data had the
following design: group (schizophrenia vs. controls) by time (baseline
vs. follow-up) by stimulus type (steady- vs. pulsed -pedestal) by SF
(0.25 c/d vs. 4 c/d). The results are summarized in Table 2. We focused
the post hoc analysis on two key issues: (i) differences between patients
and controls at baseline and follow-up; (ii) the characteristics of this
possible difference regarding stimulus type and spatial frequency. The
only signiﬁcant difference was found at 0.25 c/d in the steady-pedestalcondition in the baseline assessment: patients with schizophrenia
showed signiﬁcantly higher sensitivity compared to control individuals
(p = 0.0002). There were no other between-group differences at base-
line (p N 0.5). Similarly, at follow-up, patients and controls performed
similarly in all conditions (p N 0.5) (Fig. 3).
When we investigated within-group changes in contrast sensitivity
(baseline vs. follow-up), a marked stability was revealed in controls
(p N 0.5). In patients with schizophrenia, however, there were signiﬁ-
cantly reduced contrast sensitivity values in the steady-pedestal condi-
tion at both spatial frequencies (p = 0.0002) (Fig. 3).3.3. Motion perception
Coherence values are depicted in Table 3. The ANOVA yielded a sig-
niﬁcantmain effect of group (F(1,46) = 7.89, p b 0.05, η2 = 0.16). The
main effect of time and the interaction between group and time were
not signiﬁcant (p N 0.1). Patients with schizophrenia displayed higher
coherence threshold values compared to control individuals at baseline
and follow-up (p = 0.007).3.4. Neurocognition
RBANS composite scores are depicted in Table 3.We found signiﬁcant
main effects of group (F(1,46) = 6.96, p b 0.05, η2 = 0.13) and time
(F(1,46) = 10.74, p b 0.01, η2 = 0.19). The interaction between group
and time was signiﬁcant (F(1,46) = 11.89, p b 0.04, η2 = 0.20). Tukey
HSD tests revealed that patients with schizophrenia exhibited a signiﬁ-
cant cognitive deﬁcit at baseline (p = 0.01), but not at follow-up
(p N 0.1). At baseline, the effect size was d = 0.85, whereas at follow-
up it was d = 0.57, with a d = 0.28 improvement in patients with
schizophrenia (Tukey HSD, p b 0.01).3.5. GABA level and its relationship with visual functions
The ANOVA revealed a signiﬁcant main effect of group (F(1,46) =
6.68, p b 0.05, η2 = 0.13), but the main effect of time and the two-
way interaction were not signiﬁcant (p N 0.1). Patients with schizo-
phrenia displayed lower GABA/Cr ratio relative to control individuals
at baseline and follow-up (p b 0.05) (Table 3). There were no signiﬁ-
cant correlations between GABA/Cr ratio and visual contrast sensitivity
(−0.1 b r b 0.1, p N 0.5).
Fig. 3. Contrast sensitivity results. Data are mean (error bars: 95% conﬁdence intervals). CONT — controls, SCH — schizophrenia. *p b 0.001, SCH N CONT.
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The results of the present study indicated that short-term antipsy-
chotic treatment had a robust effect on early-stage visual functions and
anomalous perceptual experiences: there was a signiﬁcant reduction of
contrast hypersensitivity in schizophrenia, together with the ameliora-
tion of anomalous perceptual experiences. Interestingly, higher-level
motion processing was not affected during the antipsychotic treatment,
which suggests that the underlying mechanism of its impairment is
at least partly different from early-stage contrast perception. Finally,
consistent with past studies, we observed a modest improvement in
neurocognitive functions (Woodward et al., 2005, 2007).
Recent models emphasize the interaction between GABA-ergic
interneurons and glutamatergic neurotransmission in the pathophysi-
ology of schizophrenia (Gonzalez-Burgos and Lewis, 2012), possibly
modulated by dopaminergic mechanisms (Benes, 1997). We expected
that visual functions, anomalous perceptual experiences and their
changes during the treatment would be related to GABA levels in theTable 3
Motion perception, neurocognition, and GABA concentration.
Schizophrenia (n = 28) Controls (n = 20)
Motion coherence threshold (%)a
Baseline 34.9 (8.1) 28.2 (8.2)
Follow-up 35.6 (8.5) 29.2 (7.7)
RBANSb
Baseline 85.5 (11.2) 95.4 (10.5)
Follow-up 89.6 (8.4) 95.3 (10.8)
GABA/Crc
Baseline 0.08 (0.05) 0.11 (0.03)
Follow-up 0.07 (0.05) 0.11 (0.03)
Data are mean (standard deviation).
a Patients showed higher thresholds at both baseline and follow-up relative to control
individuals (Tukey HSD, p b 0.05).
b Patients showed lower RBANS (Repeatable Battery for the Assessment of
Neuropsychological Status) scores relative to control individuals at baseline, which
showed a signiﬁcant improvement at follow-up (Tukey HSD, p b 0.01).
c There were reduced GABA/Cr values in patients compared to control individuals at
both baseline and follow-up (Tukey HSD, p b 0.05) (for statistical details, see text).occipital cortex (Yoon et al., 2010). However, the data did not support
this hypothesis. The GABA level showed a deﬁnitive stability during
the treatment, which is in accordance with the results of Goto et al.
(2010) (but see Kegeles et al., 2012; Ongür et al., 2010; Tayoshi et al.,
2010; reviewed by Szulc et al., 2013). Yoon et al. (2010) showed that
GABA concentration correlatedwith visual inhibition onlywhen stimuli
consisting of multiple components were used (e.g., a center grating to
detect and amodulating surround) and there was an inhibitory interac-
tion among these components (orientation-speciﬁc surround suppres-
sion). When there was no surround, contrast perception for isolated
gratings did not depend on GABA concentration, probably because in-
teractions between inhibitory synaptic connections were not involved
(Yoon et al., 2010). Rokem et al. (2011) demonstrated that stimulus
orientation tuning was altered in early visual cortex in schizophrenia
and this tuning function was related to GABA level.
The modulatory effect of antipsychotics on contrast perception may
be distinct from cortical GABA-ergic mechanisms. Several lines of
evidence suggest that the inhibition of dopamine receptors in the retina
affects contrast processing (Bodis-Wollner, 1990). This precortical
mechanism may be responsible for the effect we observed, although
this study did not investigate this hypothesis directly.
A critical issue iswhether early-stage visual functions aremodulated
by the natural course of the illness regardless the application of antipsy-
chotic medications. We observed contrast hypersensitivity in individ-
uals at clinical high risk for psychosis (Kéri and Benedek., 2007), but
not in chronic patients (Kéri et al., 2002). In chronic patients, contrast
sensitivity was related not only to antipsychotic dose (Kéri et al.,
2002), but also to negative symptoms (Slaghuis, 1998). Similarly,
dysfunctions of attention may interfere with contrast processing (Kéri
et al., 1999). Preliminary evidence from chronic patients with schizo-
phreniawhodid not receive antipsychotics at least for 4 weeks suggests
decreased contrast sensitivity relative to controls (unpublished obser-
vation), although the long-term effects of previously applied antipsy-
chotics cannot be excluded. Another methodological confound may be
hidden ophthalmological alterations in chronic patients, often suffering
from a poor general medical condition.
The possible differential effect of disease stage andmedication status
on cortical GABA concentrations also needs further investigation
because the results are not conclusive. In the Yoon et al. (2010) study,
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chronic and recent onset patients with schizophrenia was included.
In contrast, Ongür et al. (2010) demonstrated elevations in GABA in
the parieto-occipital cortex of patients with chronic schizophrenia.
Finally, Kegeles et al. (2012) reported elevations in GABA levels in the
medial prefrontal cortex but not the dorsolateral prefrontal cortex of
unmedicated patients (mean duration of illness: 7 years), whereas
medicated patients (mean duration of illness: 9 years) did not display
elevated GABA levels.
The ﬁnding that contrast hypersensitivity and the effect of antipsy-
chotics were the most pronounced in the steady-pedestal condition at
low spatial frequency suggests the pivotal role of putative M pathways,
which may be implicated in the development of anomalous perceptual
experiences (Kéri et al., 2005; Kiss et al., 2010). The overactivity of M
pathways (transient channels)was also raised in the backwardmasking
literature of schizophrenia (Green et al., 1994). This hypothesis should
be conﬁrmed by the direct visualization of M and P pathways at the
precortical level. However, the relationship between altered general
perceptual processing and the classic clinical symptoms of schizophre-
nia is still controversial. Javitt (2009) postulated that basic perceptual
processes, localized to precortical channels and primary sensory regions
of the cortex, are responsible for bottom-up deﬁcits in cognitive pro-
cessing. In the visual system, for example, M pathway impairments
may result in higher-order deﬁcits in perceptual organization (i.e., as-
sembling parts into whole objects), object recognition, processing of
facial expressions, and reading (Javitt, 2009). These may be related to
negative symptoms and social dysfunctions. Anomalous visual percep-
tual experiences, on the other hand, are prevalent in the early phase
of the illness (Klosterkötter et al., 2001), and, as shown by the present
study, display a rapid response to antipsychotic treatment.
Themost important aimof future research is to explore the relevance
of these ﬁndings in terms of everyday clinical practice. A comprehensive
assessment is necessary to reveal the usefulness of the investigation of
anomalous perceptual experiences and related psychophysical mecha-
nisms in the early recognition of schizophrenia and in the monitoring
of therapeutic response.
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